PDL1Binder: Identifying programmed cell death ligand 1 binding peptides by incorporating next-generation phage display data and different peptide descriptors

Monoclonal antibody drugs targeting the PD-1/PD-L1 pathway have showed efficacy in the treatment of cancer patients, however, they have many intrinsic limitations and inevitable drawbacks. Peptide inhibitors as alternatives might compensate for the drawbacks of current PD-1/PD-L1 interaction blocker...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Bifang, Li, Bowen, Chen, Xue, Zhang, Qianyue, Lu, Chunying, Yang, Shanshan, Long, Jinjin, Ning, Lin, Chen, Heng, Huang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335124/
https://www.ncbi.nlm.nih.gov/pubmed/35910615
http://dx.doi.org/10.3389/fmicb.2022.928774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335124/
https://www.ncbi.nlm.nih.gov/pubmed/35910615
http://dx.doi.org/10.3389/fmicb.2022.928774

Ejemplares similares